Retroviral gene transfer in autologous bone marrow transplantation for adult acute leukemia

To evaluate whether marrow contributes to relapse after autologous bone marrow transplantation (AuBMT) for acute leukemia, transplanted marrow was marked with the G1N retroviral vector (Genetic Therapy Inc.) containing the neomycin phosphotransferase gene (neo), Between April 1992 and August 1993, 4 patients were transplanted for acute myeloid leukemia (AML) in second complete remission (CR) and 1 patient for acute lymphoid leukemia in first CR, An average of 12.4% (range 5-19%) of transplanted marrow mononuclear cells were exposed to G1N vector for 4 hr, In the vector-treated portion of the marrow, 4.9% of GM-CFU and 3.6% of erythroid burst-forming units (BFU-E) were resistant to G418 in vitro, In the 5 patients, the polymerase chain reaction (PCR) detected the neo sequence on only two occasions after AuBMT, Of 4 patients surviving 1 year after transplantation, only 1 had evidence of gene marked cells by PCR, Two AML patients have relapsed, one of whom had evidence of neo sequences in the bone marrow at day 100 but not at relapse 11 months after AuBMT, The second patient relapsed 18 months after AuBMT but never had PCR evidence of neo sequences before or after relapse, Our results indicate vector-transduced autologous bone marrow from heavily pretreated adults with acute leukemia mark with low efficiency, although vector sequences have been detected in bone marrow and peripheral blood up to 1 year after transplant, Of the 2 relapsed patients, no evidence of vector-marked leukemic blasts have been detected.